The products of the cytochrome P450 (CYP) genes play an important role in the detoxification of xenobiotics and environmental contaminants, and many foreign chemicals or xenobiotics can induce their expression. We have previously shown that the nuclear hormone receptor CAR (Constitutive Androstane Receptor, NR113) mediates the well studied induction of CYP2B10 gene expression by phenobarbital (PB) and 1, 4-bis-[2-(3, 5,-dichloropyridyloxy)] benzene (TCPOBOP). We have used the CAR knockout mouse model to explore the broader functions of this xenobiotic receptor. In addition to the liver, CAR is expressed in the epithelial cells of the villi in the small intestine, and this expression is required for CYP2B10 induction in response to PB and TCPOBOP in those cells. In agreement with previous observations that CAR can bind to regulatory elements in CYP3A genes, CAR is also required for induction of expression of CYP3A11 in response to both PB and TCPOBOP in liver. In males, CAR is also required for induction of liver CYP2A4 expression. In wild type animals, pretreatment with the CAR inverse agonist androstenol blocks the response of both the CYP2B10 and CYP3A11 genes to PB and TCPOBOP, and decreases basal CYP3A11 expression. CAR is also required for the response of CYP2B10 to several additional xenobiotic inducers, including chlorpromazine, clotrimazole and dieldrin, but not dexamethasone, an agonist for both the xenobiotic receptor PXR (Pregnane X Receptor NR112) and the glucocorticoid receptor. Chlorpromazine induction of CYP3A11 is also absent in CAR-deficient animals, but the responses to clotrimazole and dieldrin are retained, indicating that both of these inducers can also activate PXR (Pregnane X Receptor NR112). We conclude that CAR has broad functions in xenobiotic responses. Some are specific to CAR but others, including induction of the important drug metabolizing enzyme CYP3A, overlap with those of PXR.
INTRODUCTION
Cytochrome P450 (CYP) enzymes play a significant role in metabolism of both endogenous hormones and structurally diverse foreign chemicals. Exposures to foreign compounds or xenobiotics can lead to increased expression and activity of many CYP proteins and other drug metabolizing enzymes. [1] [2] [3] This induction of CYP genes can have a major impact in CYP-dependent drug metabolism and drug-drug interactions of foreign chemicals. 4, 5 One major group of CYP inducers, the structurally diverse phenobarbital (PB)-like compounds, induces a subset of CYP genes within the CYP1A, 2A, 2B, 2C, and 3A family.
1,2 A significant advance in understanding the widely studied induction of CYP2B genes by PB and a number of other PB-like inducers was the identification of an upstream element, termed the PB response element module (PBREM), required for this response. 6, 7 A role for the nuclear receptor CAR (constitutive androstane receptor, NR113) in this induction was suggested by the demonstration that this element contains two binding sites for CAR/RXR heterodimers. 8 Further studies demonstrated that the highly potent PB-like inducer, TCPOBOP (1,4-bis[2-(3,5-dichloropyridyloxy)]benzene) can increase CAR transactivation 9 and functions as an agonist ligand. 10 The significance of this activation was firmly established by the complete absence of induction of the CYP2B10 gene in liver in response to PB or TCPPOBOP in mice lacking the CAR gene. 11 These mice also lost the liver hypertrophic and hyperplastic responses to these inducers and showed decreased drug metabolizing capability. Thus, these findings indicated that CAR is a novel xenobiotic receptor that confers PB responses in vivo.
The closest relative to CAR within the nuclear receptor superfamily is a protein referred to as PXR (pregnane X receptor, NR112) 12 or SXR (in humans). 13 An extensive series of studies have demonstrated that PXR is also a xenobiotic receptor that plays a key role in activation of CYP3A genes in response to a wide range of compounds. [14] [15] [16] While the functions of CAR in regulation of CYP2B gene expression and PXR in regulation of CYP3A expression are now clear, several lines of evidence suggest that this specificity is not absolute, and that the functions of these two nuclear receptors overlap. Thus, biochemical studies have demonstrated that PXR can bind to the CAR binding sites in the PBREM, and that CAR can bind to the PXR response elements identified in CYP3A genes. 10, 17 Partial overlap has also been demonstrated at the level of ligand binding. 16 These results raise a number of important questions regarding the specificity of xenobiotic responses.
We have pursued this issue by addressing several aspects of the function of CAR. The construct used to generate the CAR-deficient animals replaces the initial coding exons of the CAR gene with a ␤-galactosidase reporter, and we have used this reporter to further characterize CAR expression. In addition to liver, CAR is expressed in the epithelial cells of the villi of the small intestine. CAR-deficient animals are also defective in induction of CYP2B10 gene expression in these cells in response to PB and TCPOBOP. We have also used the CAR knockout animals to identify both CYP2A4 and CYP3A11 as direct targets of CAR, and to examine the relative roles of CAR and PXR in response to a series of additional xenobiotic inducers. These studies both identify specific functions of CAR and PXR and confirm their functional overlap, particularly in regulation of CYP3A gene expression.
RESULTS

Tissue-specific Expression of CAR
In the previously described CAR knockout animals, 11 the ␤-galactosidase gene replaces the first two exons of the CAR gene. Thus, ␤-galactosidase expression serves as a reporter for CAR promoter activity in these animals. X-Gal staining with CAR ϩ/Ϫ heterozygous mice was used to examine the
The Pharmacogenomics Journal expression profile of CAR in various embryonic stages and 8-week-old mice. In the developing animals, ␤-galactosidase expression was not seen in the liver until the perinatal stage at E19. This correlates well with the extremely limited inducibility of the PB responsive CYP2B1 and CYP2B2 genes in the rat at this stage. 18 As expected, liver ␤-galactosidase expression was relatively high in adult animals (Figure 1A , a; 1B, a). In adults, ␤-galactosidase activity was also observed in small intestine (Figure 1A, b; Figure 1B , b), and stomach ( Figure 1B, c) . Histologically, ␤-galactosidase activity was observed in hepatocytes in the liver and the epithelial cells of the villi in the small intestine ( Figure 1B, a and b) . Expression was also observed in an unidentified subset of cells in the sub-mucosal layer of the stomach that, based on their reported expression of CYP3A, 19 may be parietal cells ( Figure 1B, c) . No detectable ␤-galactosidase activity was observed in the heart, lung, spleen, mammary gland, uterus or ovary (data not shown). 
CAR is Essential for Induction of the PB-responsive Genes
We have previously shown that CAR mediates specific induction of the mouse CYP2B10 transcript by PB or TCPO-BOP in the liver. 11 Using a monoclonal antibody against rat CYP2B1, a homologue of mouse CYP2B10, we also detected significant induction of CYP2B10 protein in PB-or TCPO-BOP-treated wild-type mice. This induction is completely lost in the CAR knockout mice (Figure 2b) . Similar results were observed in the small intestine, where both inducers increased CYP2B10 expression in the wild-type but not the knockout animals ( Figure 3a) . As expected, induction of CYP2B mainly occurred in the epithelial cells of the villi, in which CAR is expressed (Figure 3b) .
Phenobarbital is well known to induce additional cytochrome p450s and other drug metabolizing enzymes. [1] [2] [3] To begin to define the role of CAR in such responses, we studied expression of two additional genes reported to be induced by PB and TCPOBOP, CYP3A11 and CYP2A4. 20 CYP3A11 was of particular interest because CAR has been shown to bind to the ER-6 element from human CYP3A4 and the DR-3 element from rat CYP3A1, 10, 17 and because of the well known importance of CYP3A enzymes in drug metabolism. In the wild-type animals, both CYP3A11 mRNA and protein were induced by both xenobiotics, with a particularly strong response to TCPOBOP. Loss of CAR expression did not have a large effect on the somewhat variable basal levels of CYP3A11 expression. This is consistent with the fact that in untreated animals CAR is sequestered in the cytoplasm of wild-type hepatocytes, and thus should not contribute to basal CYP3A11 expression. In contrast, the induction of CYP3A11 in the xenobiotic-treated groups was clearly absent in the CAR-deficient animals ( Figure 4 ). These results demonstrate that CAR, like PXR, 15 is able to activate CYP3A gene expression in response to appropriate inducers.
Expression of CYP2A4 is sexually dimorphic, with high levels in female liver and much lower levels in male liver. 21 This is thought to be due to differential effects of pulsatile and more constant levels of growth hormone in males and females. Interestingly, CAR-mediated induction of CYP2A4 by PB or TCPOBOP was also sexually dimorphic: significant induction of CYP2A4 was observed in wild-type, but not knockout male animals ( Figure 5 ). The higher basal levels of expression in female animals were not responsive to either inducer (data not shown). It is unclear whether the differ- ences in growth hormone responses or other factors such as differences in endogenous CAR ligands contribute to this lack of response. We conclude that CAR mediates induction of all three of the CYP genes tested in response to the two xenobiotics, and is likely to mediate the response of other genes to the PB-like inducers.
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one injection of T for 24 h followed by three injections of A (one injection per day) (T → A → A → A); lane 4, one injection of T for 1 day (→ → T →); lane 5, three injections of A for 3 days (one injection per day), and one injection of T was given in between the last two doses of A (A → A → T → A); lane 6, three injections of A for 3 days (one injection per day) (A → A → A →).
Twenty micrograms of total liver RNA were subjected to Northern blot analysis. The blot probed with CYP2B10 was exposed for 24 h, the blot probed with CYP3A11 was exposed for 16 h and the control 18S probe was exposed for 4 h.
Androstenol Pretreatment Blocks the Response to TCPOBOP
Previous studies show that while TCPOBOP acts directly as a CAR agonist, the inverse agonist androstenol can block TCPOBOP activation by dissociating the coactivator SRC-1 (steroid receptor coactivator-1) from the CAR ligand binding domain. 10, 22 To determine whether androstenol can also abolish TCPOBOP-enhanced expression of endogenous CAR target genes, we performed two sets of 4-day treatments with wild-type male mice. In the first set, one group of mice received corn oil only at day 1 (CO → -→ -→ -). The other group was injected with one dose of TCPOBOP (0.3 mg kg Ϫ1 ) and treated for 4 days (T → -→ -→ -). The last group received three injections of androstenol (150 mg kg
Ϫ1
, one injection per day) 24 h after TCPOBOP treatment (T → A → A → A). As expected, in the absence of any ligands basal expression of CYP2B10 was undetectable and that of CYP3A11 was low ( Figure 6 , lane 1). TCPOBOP treatment strongly stimulated expression of both genes (lane 2). Androstenol treatment following TCPOBOP injection only slightly inhibited TCPOBOP activation of both genes (lane 3).
In the second set of treatments, one group of mice was treated with TCPOBOP at day 3 (-→ -→ T → -). The other group of mice was treated with three injections of androstenol (one injection per day). These mice also received one dose of TCPOBOP in between the second and the third dose of androstenol (A → A → T → A). Twenty-four hours after the last injection of androstenol, the mice were killed. The last group of mice was treated with three doses of androstenol only (A → A → A → -). In striking contrast to the limited effects of the inverse agonist after TCPOBOP pretreatment, pretreatment with androstenol completely abolished TCPOBOP induction of both CYP2B10 and 3A11 genes (compared to lanes 4 and 5). Interestingly, androstenol alone substantially decreased CYP3A11 expression (lane 6).
As just noted, complete loss of CAR activity does not affect basal expression of CYP3A11, which is consistent with the cytoplasmic localization of this receptor under ordinary circumstances. However, treatment with inverse agonists results in generation of a transcriptionally silent CAR/RXR complex 22 that could account for the direct negative effect of the androstenol-bound CAR. For example, this inactive complex could displace basal levels of activated PXR or other transcription factors from the CYP3A11 promoter. Although it is also possible that the inverse agonist-bound CAR functions as an active transcriptional repressor in this context, we have not observed such activity in transient transfections and have not observed inverse agonist-dependent recruitment of corepressors. Overall, these results demonstrate that the inverse agonist can block CAR activation in vivo, and suggest that this inhibition of CAR activity may significantly impair the capacity of the liver to respond to xenobiotics.
CAR Mediates Responses of CYP2B and CYP3A Genes to Diverse Chemicals
It has been previously reported that a wide variety of compounds, including drugs, organic solvents, polychlorinated biphenyls, pesticides and plant products can stimulate expression of CYP2B10 in primary hepatocytes. 23 In order to determine whether CAR mediates the responses of CYP2B10 to such structurally diverse inducers, we treated the animals with the antipsychotic agent chlorpromazine, the pesticide dieldrin, the antifungal clotrimazole, and the synthetic steroid dexamethasone. CYP2B10 mRNA levels were induced by all four compounds in wild-type animals ( Figure 7 ). In the cases of chlorpromazine, dieldrin and clotrimazole, this induction was completely absent in the CAR knockout mice, providing compelling evidence that CAR mediates CYP2B10 response to all three of these inducers. As expected from its function as an activator of both the glucocorticoid receptor and PXR, but not CAR, the dexamethasone response was retained in the CAR knockout mice. 11, 15, 24 The lack of dexamethasone response in glucocorticoid receptor-deficient animals indicates that this receptor is the predominant inducer of CYP2B10 expression. 24 The effects of these compounds on CYP3A11 expression were also examined in the wild-type and CAR knockout animals. Chlorpromazine treatment did not change CYP3A11 expression (data not shown). However, dieldrin, clotrimazole, and dexamethasone greatly increased CYP3A11 mRNA levels in both wild-type and CAR null mice (Figure 7b ). Based on previous results, 12, 16 we assume that all of these www.nature.com/tpj responses in the CAR knockout animals are based on PXR activation, although it remains possible that the glucocorticoid receptor could contribute to the dexamethasone responses. 24 While TCPOBOP is a direct agonist ligand for CAR, PB does not appear to bind CAR. Instead, induction of CAR target genes is thought to be an indirect consequence of the translocation of CAR from cytoplasm to nucleus in PB-treated hepatocytes. 25, 26 Dexamethasone has also been reported to induce nuclear translocation of CAR in primary human hepatocytes, although this does not result in induction of CYP2B gene expression. 27 Two approaches were taken to determine whether the various compounds act as CAR or PXR ligands. In the first, the ability of the compounds to activate chimeras consisting of the DNA binding domain of Gal4 fused to either CAR or PXR was tested. In the second, the effect of the compounds on coactivator recruitment was examined using a mam-malian two-hybrid assay based on chimeras consisting of the VP16 activation domain joined to CAR or the PXR ligand binding domain, and the Gal4 DNA binding domain fused to the receptor interaction domain from the coactivator SRC-3. As expected, from previous results, the potent agonist TCPOBOP efficiently activated the Gal4-CAR chimera (Figure 8a ) and promoted coactivator binding (Figure 8b ), while PB did neither. The negative control retinoic acid and the PXR ligands PCN and dexamethasone were also inactive. However, chlorpromazine, clotrimazole and dieldrin all significantly activated the Gal4-CAR chimera and at least modestly stimulated coactivator recruitment. Thus, all three of these compounds appear to function directly as CAR agonists.
With PXR, the best activation of the Gal4-PXR chimera (Figure 8c ) and coactivator recruitment (Figure 8d) was seen with the known ligands PCN and dexamethasone. Although SXR/hPXR has been reported to be activated by TCPOBOP and PXR, the murine PXR is not. 13, 14 Thus, the lack of effects of these compounds and retinoic acid was not surprising. The lack of effect of chlorpromazine was consistent with the lack of induction of CYP3A mRNA in the CAR knockout animals. Thus, this compound, like TCPOBOP, is a specific activator of CAR. In contrast, modest but significant activation and coactivator recruitment was observed with clotrimazole, and a more potent response was observed with dieldrin. These results, which are also consistent with the CYP3A responses in the CAR knockout animals, indicate that these two compounds function as agonists for both CAR and PXR. Overall, we conclude that among the series of inducers of CYP gene expression tested in the knockout animals, TCPO-BOP, PB and chlorpromazine are specific activators of CAR (though PB does not function as a CAR agonist), dexamethasone is a specific activator of PXR, and dieldrin and clotrimazole activate both xenobiotic receptors.
DISCUSSION
Drug exposure can lead to an increased expression of specific CYP enzymes as well as other drug-metabolizing proteins. The induction of these genes by xenobiotic chemicals is a common defense mechanism against the toxicity and carcinogenicity of foreign compounds. This xenobiotic response can also greatly augment the metabolism and clearance of therapeutic drugs. Major advances in our understanding of the molecular basis for the induction of CYP genes by xenobiotics are being provided by the characterization of the functions of the newly identified xenobiotic receptors CAR and PXR/SXR. 2, 3 One of the best characterized of the xenobiotic responses is the induction of CYP2B and other genes by PB and a number of other structurally unrelated compounds. [1] [2] [3] Results with CAR knockout animals have clearly demonstrated that CAR mediates the induction of the CYP2B10 gene in response to the inducers PB and TCPOBOP in the liver. 11 In this study, we have confirmed this conclusion and extended it to show that CAR is also required for CYP2B10 induction in the small intestine. We have also examined the role of CAR in the responses to several additional xenobiotics. As
The Pharmacogenomics Journal expected, the activation of CAR by TCPOBOP can be prevented by the inverse agonist ligand androstenol, though the basis for the striking and unexpected effects of the order of addition of the inhibitor and the activator remain to be explained. Perhaps more importantly, we have also found that CAR is essential for CYP2B10 induction in response to a wider range of compounds, including chlorpromazine, dieldrin and clotrimazole. Thus, CAR is clearly able to mediate the effects of a diverse group of xenobiotic inducers.
Previous results have suggested a significant overlap between the activators of murine CAR and PXR, raising a number of intriguing questions regarding specificity. This issue is complicated substantially by the issue of species differences, since the sequences of the ligand binding domains of both of these xenobiotic receptors differ significantly between rodents and humans and the corresponding receptors can show quite different responses to various compounds. For example, the human CAR protein does not appear to bind or respond to TCPOBOP, a highly potent agonist for murine CAR. 10, 16 Similarly, the rodent PXR is unable to respond to rifampicin, a potent agonist of SXR/human PXR. 13, 14 Within the context of the murine proteins, however, the in vivo functional results described here are quite consistent with previous primarily biochemical results demonstrating that CAR and PXR share several ligands. 16 Functionally, this overlap may be clearest in the case of clotrimazole, which has now been examined in both CAR and PXR knockout animals. Our results demonstrate that clotrimazole treatment results in CAR activation and induction of CYP2B10 expression. Studies by Xie et al, 17 demonstrate that clotrimazole-activated CAR can also contribute to CYP3A11 expression, since this response is retained in the absence of PXR function. Finally, clotrimazole, which activates both PXR and SXR/hPXR in transfections and binds directly to at least the latter, 16 can also activate PXR in vivo, since the results described here show that loss of CAR does not prevent the induction of the PXR target CYP3A11.
Although the effects of dieldrin have not been examined in the PXR-deficient animals, the results described here demonstrate that it can activate both receptors in transfections and also promote coactivator recruitment to both. In vivo, it can also activate both CAR, as demonstrated by loss of CYP2B10 induction in the CAR knockouts, and PXR, as suggested by the retention of the CYP3A11 response in these animals.
The potent activation of CYP3A11 expression in response to TCPOBOP and its loss in CAR knockout animals clearly demonstrates that CAR can activate CYP3A expression. Thus, the functional overlap between CAR and PXR extends to target genes. This conclusion is consistent with previous studies demonstrating the ability of CAR/RXR heterodimers to bind to and transactivate previously characterized binding sites for PXR/RXR heterodimers in CYP3A genes. 10, 17 Vice versa, PXR/RXR heterodimers have also been shown to bind to and transactivate the CAR/RXR binding sites from the CYP2B10 or CYP2B6 genes. 10, 17, 28 This activation of CAR targets by PXR is consistent with the effects of the additional PXR specific agonists in wild-type mice or human hepatocytes, and also the effects of a constitutively active VP16-SXR protein in transgenic animals. 17, 28 It should be emphasized that the overlap between CAR and PXR is not complete. There are murine CAR activators that are ineffective on PXR (TCPOBOP, PB, chlorpromazine) www.nature.com/tpj and PXR activators that do not activate CAR (dexamethasone, PCN). Thus it is apparent that each receptor mediates a specific subset of the xenobiotic response. It is not possible to predict whether a particular compound would activate CAR, PXR or both, considering the great structural diversity of the compounds that function directly as ligands for the two proteins and also the compounding effects of both species differences and the indirect activation of CAR by PB and presumably other compounds. Such determinations will require careful characterization incorporating not only biochemical studies of ligand binding, but also in vivo functional studies.
The results described here suggest the existence of an intriguing additional level of complexity and specificity in the functions of both CAR and PXR that is based on differential effects of different inducers. While the potent CAR agonist TCPOBOP is an effective inducer of both CYP2B10 and CYP3A11, CAR activation by chlorpromazine only induces the former. Thus, induction of CYP2B10 expression appears to be a consistent consequence of CAR activation, while the CYP3A11 response is not. Similarly, the activation of PXR consistently results in CYP3A11 induction, but among the compounds examined here only dexamethasone induced CYP2B10 expression in the CAR knockout animals, and this effect is thought to be due to the glucocorticoid receptor. 24 It is possible that the breadth of the response to a particular treatment is a relatively simple reflection of the potency of receptor activation. Alternatively, individual inducers could have more complex differential effects on the conformation of the activated receptors. This would be consistent with detailed studies of the estrogen receptor demonstrating that binding of even closely related agonists or antagonists can induce distinct receptor conformations. 29 These differential responses complicate interpretation of the already complex effects of various inducers of these two genes and other targets in vivo. Particularly as the number of identified targets for the two receptors increases, it will be interesting to determine whether different activators of a specific receptor induce distinct patterns of target genes.
Overall, we conclude that CAR plays a much broader role in xenobiotic response than simply mediating response of CYP2B10 to PB-like inducers. The central role of CAR in CYP2B and 3A gene induction has wide implications, not only in the mechanism of gene regulation, but also in the understanding of the toxicological effects of environmental contaminants and drug-drug interactions. CYP3A enzymes catalyze the metabolism of up to 60% of various commonly used drugs, 30, 31 and the induction of this expression by one drug can have significant undesirable consequences on the effects of another. The results described here suggest that the use of cell culture-or transgenic animal-based test systems employing the human CAR protein may facilitate the identification of known drugs or drugs in development that show such undesirable drug-drug interactions. This should allow the development of safer drugs that retain desirable therapeutic activity but not undesirable effects on drug metabolism.
MATERIALS AND METHODS
Animal Treatment
At least three mice between 8-10 weeks old were used for each treatment. Mice were treated by intraperitoneal injection with corn oil, PB (100 mg kg ) for indicated times. All compounds were purchased from Sigma (St Louis, MO, USA) unless indicated. For androstenol treatment, the dose for TCPOBOP was 0.3 mg kg Ϫ1 and androstenol 150 mg kg Ϫ1 (Steraloids Inc, Newport, RI, USA). For 3-day PB or androstenol treatment, mice were injected intraperitoneally three times with the compound, one injection per day.
X-Gal (5-Bromo-4-chloro-3-indolyl-␤-D-galactoside) Staining
Liver tissues were fixed at 4°C for 1 h with freshly made 4% paraformaldehyde in PBS then embedded in Tissue Freezing Medium (Triangle Biomedical Sciences, Durham, NC, USA). Whole tissues or frozen sections of liver were stained for 1.5 h at 37°C with a staining solution containing 1 mg ml Ϫ1 X-gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl 2 , 0.01% deoxycholate, 0.02% NP-40, 100 mM phosphate buffer, pH 7.3. Embryos or adult small intestine and stomach tissues were fixed at room temperature for 2 h with fixative containing 0.2% glutaraldehyde, 1.5% formaldehyde, 5 mM EGTA, 2 mM MgCl 2 , 100 mM sodium phosphate, pH 7.3. Whole-mount staining of embryo and adult small intestine and stomach were performed at 37°C overnight with the same staining solution described above. They were then either preserved in 3.7% formaldehyde or dehydrated and processed through Histo-Clear (National Diagnostics, Atlanta, GA, USA) embedding in paraffin. The sections were counter-stained with Nuclear Fast Red (Trevigen, Gaithersburg, MD, USA).
Northern Blot Analysis
Total RNA (20-30 g) from individual mouse livers was subjected to Northern blot analysis. Preparation of probes for CYP2B10 was previously described. 11 Probes for CYP3A11 and CYP2A4 were prepared by RT-PCR with mouse liver total RNA using the Superscript One-step RT-PCR System (Life Technologies). PCR primers for CYP3A11 were 5Ј-ccg cct cta gat gag atc gat gag gct ct-3Ј and 5Ј-ccg ccg gat cct gcc ttt ctg aag aac tc-3Ј. The primers for CYP2A4 were 5Ј-ccg cct cta gaa ggg tca cca agg aca cc-3Ј and 5Ј-ccg ccg gat ccc cct tct ctg gct acc ttt-3Ј.
Western Blot Analysis
Mouse liver total protein was prepared by sonicating the tissues in Laemmli sample buffer without ␤-mecaptoethanol. Ten micrograms of total protein were electrophoresed on 10% polyacrylamide gels, and immunoblotted with monoclonal anti-rat CYP2B1 (BE28.2) or anti-rat CYP3A1 (Ig8) antibodies (provided by Dr Erin G Schuetz, St Jude Children's Research Hospital, Memphis, TN, USA). Both primary antibodies were followed by appropriate secondary antibodies coupled with horseradish peroxidase and developed with the enhanced chemiluminescence detection reagent ECL (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
In Situ Hybridization
Paraffin sections of adult small intestine were used in this study. A fragment of CYP2B10 was amplified with RT-PCR as described 11 and subcloned into Xba I and BamH I sites of pBluescript (Stratagene, La Jolla, CA, USA). This vector was linearized with Xba I. T7 polymerase was used to synthesize [ 35 S]-labeled antisense CYP2B10 probes. Labeled probes were hybridized to tissue sections and mRNA expression was detected by film emulsion with autoradiography. Sections were counter-stained with Hematoxylin and then examined using light-and dark-field microscopy.
Cell Culture and Transfections
HepG2 cells were maintained in Dulbecco's modified Eagle medium, supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA). For the transfections HepG2 cells were plated into 24-well dishes with Dulbecco's modified Eagle medium supplemented with 10% charcoalstripped serum and transfected using the calcium phosphate precipitation method as described previously. 10 The cells were washed with phosphate-buffered saline 12 h after transfection and ligands were added. Transfections included 200 ng of luciferase reporter plasmid, 50 ng ␤-galactosidase internal control plasmid (pCMX-␤-galactosidase), 50-100 ng of pCMX expression vectors for GAL4 and/or VP16 fusion proteins and pGEM4 plasmid DNA to bring the total DNA to 1 g per well. Cells were harvested and assayed for luciferase activity 24 h after the addition of the ligands, and reporter expression was normalized to the ␤-galactosidase activity (Tropix, Bedford, MA, USA), according to the manufacturer's directions. Each data point represents the average of a quadruplicate experiment, and similar results were replicated in at least three independent experiments.
Plasmids
The pCMX-GAL4, pCMX-VP16, pCMX-GAL4-mCAR-LBD fusion, 10 pG5E1b-Luciferase reporter and pCMX-GAL4-SRC-3 RID 32 have been described previously. pCMX-GAL4-hPXR-LBD was generated by PCR amplification of cDNA encoding amino acids 105-434 of hPXR using oligonucleotides 5Ј-GCGGGTACCAAGAAAGAGATGATCATGTCCGATGCCG CTG-3Ј and 5Ј-GGGTGTGGGGGATCCTCAGCTACCTG TGATGCCG-3Ј and insertion into pCMX-VP16 vector via Asp718/BamHI sites, with the sequence confirmed by in vitro translation and sequencing.
